论文部分内容阅读
类风湿性关节炎(RA)是以关节滑膜炎为特征的自身免疫性疾病(AID),细胞因子(CK)贯穿RA的整个病程。重要的CK如TNF-α、白细胞介素-1β(IL-1β)在促进关节滑膜细胞增生和炎症进程中起举足轻重的作用。近年来,临床对RA的治疗主要以这些CK为靶点,然而TNF-α、IL-1β阻断剂只对部分患者有效,逐渐增多的不良反应如继发感染、恶性肿瘤的发生等也逐渐引起关注。白细胞介素-6(IL-6)的异常表达和失调与RA的病情密切相关,是RA发病的重要调控因子,阻断剂可能用于RA的临床治疗。
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis (AID) throughout the course of RA. Important CKs such as TNF-α and IL-1β play a pivotal role in promoting synovial cell proliferation and inflammation. In recent years, clinical treatment of RA mainly targets these CKs. However, TNF-α and IL-1β blockers are effective only in some patients. Increasing adverse reactions such as secondary infection and malignant tumors gradually attract attention. Aberrant expression and dysregulation of interleukin-6 (IL-6) are closely related to the severity of RA and are important regulators of RA pathogenesis. Blockers may be used in the clinical treatment of RA.